The potential rescheduling of cannabis to Schedule III has been met with a mix of celebration and skepticism within the industry. While many view this as a significant step forward, I find myself in the camp of cautious observers. As someone who has closely followed and written about cannabis policy, I’ve long maintained that Schedule III is less about progress and more about creating a sweet spot for Big Pharma to dominate the cannabis market, leaving smaller players and consumers at a disadvantage.
Members of Outlawz have said for years that they mixed some of Tupac Shakur’s ashes…
State and local police made at least 218,152 marijuana-related arrests in 2025, including 200,960 for…
Three days in Philadelphia, September 25 to 27, with a free record-clearing clinic and a…
Four decades after its Amsterdam beginnings, Barney’s Farm is marking the milestone with new markets,…
Gallup’s new numbers hold a small, awkward pattern: the Americans most convinced cannabis is bad…
The FDA is seeking outside data and analytics services to better understand how people use…